Shots:

• MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. The transaction is expected to close in Q3’21
• The acquisition will bolster Morphosys’ position in hematology-oncology & accelerates growth strategy with the addition of Constellation’s Pelabresib (CPI-0610) & CPI-0209
• Additionally- MorphoSys enters into a strategic funding partnership with Royalty Pharma- under which MorphoSys will receive $1.425B as up front- $350M as development funding bonds- $150 as milestones. Royalty Pharma will receive royalties and is expected to invest $100M in a cash capital increase of MorphoSys

  Ref: Businesswire | Image: Constellation Pharmaceuticals